Kiniksa Pharmaceuticals International, plc
KNSAFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Kiniksa Pharmaceuticals International, plc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 9 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 2, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Uniplan Investment Counsel, Inc. | 2026-03-31 | 493 | $23.7K | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2026-03-31 | 15,068 | Not shown | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2025-12-31 | 21,543 | Not shown | SEC filing |
| Birchview Capital, LP | 2025-09-30 | 30,000 | Not shown | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2025-09-30 | 20,700 | Not shown | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2025-06-30 | 70,926 | Not shown | SEC filing |
| Birchview Capital, LP | 2025-06-30 | 30,000 | Not shown | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2025-03-31 | 77,722 | Not shown | SEC filing |
| Birchview Capital, LP | 2025-03-31 | 30,006 | Not shown | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2024-12-31 | 98,093 | Not shown | SEC filing |
| Birchview Capital, LP | 2024-12-31 | 30,000 | Not shown | SEC filing |
| Birchview Capital, LP | 2024-12-31 | 30,000 | Not shown | SEC filing |
| Birchview Capital, LP | 2024-09-30 | 30,000 | Not shown | SEC filing |
| HARBOR CAPITAL ADVISORS, INC. | 2024-09-30 | 97,543 | Not shown | SEC filing |
| Birchview Capital, LP | 2024-09-30 | 30,000 | Not shown | SEC filing |
| OSAIC HOLDINGS, INC. | 2024-06-30 | 623 | Not shown | SEC filing |
| ADIRONDACK TRUST CO | 2024-06-30 | 875 | Not shown | SEC filing |
| CWM, LLC | 2024-06-30 | 451 | Not shown | SEC filing |
| Birchview Capital, LP | 2024-06-30 | 30,000 | Not shown | SEC filing |
| BARCLAYS PLC | 2024-06-30 | 34,839 | Not shown | SEC filing |
- Each value is checked against Kiniksa Pharmaceuticals International, plc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at Kiniksa Pharmaceuticals International, plc's share price.
- Value not shown for 17 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- HARBOR CAPITAL ADVISORS, INC.: 21,543 shares reported 2025-12-31; 15,068 shares reported 2026-03-31.
- HARBOR CAPITAL ADVISORS, INC.: 20,700 shares reported 2025-09-30; 21,543 shares reported 2025-12-31.
- HARBOR CAPITAL ADVISORS, INC.: 70,926 shares reported 2025-06-30; 20,700 shares reported 2025-09-30.
- Birchview Capital, LP: 30,000 shares reported 2025-06-30; 30,000 shares reported 2025-09-30.
- HARBOR CAPITAL ADVISORS, INC.: 77,722 shares reported 2025-03-31; 70,926 shares reported 2025-06-30.
- Birchview Capital, LP: 30,006 shares reported 2025-03-31; 30,000 shares reported 2025-06-30.
- HARBOR CAPITAL ADVISORS, INC.: 98,093 shares reported 2024-12-31; 77,722 shares reported 2025-03-31.
- HARBOR CAPITAL ADVISORS, INC.: 97,543 shares reported 2024-09-30; 98,093 shares reported 2024-12-31.
- Birchview Capital, LP: 30,000 shares reported 2023-12-31; 30,000 shares reported 2024-03-31.
- BARCLAYS PLC: 185,756 shares reported 2023-12-31; 42,147 shares reported 2024-03-31.
- JPMORGAN CHASE & CO: 45,970 shares reported 2023-12-31; 22,185 shares reported 2024-03-31.
- NEW YORK STATE COMMON RETIREMENT FUND: 34,867 shares reported 2023-12-31; 39,771 shares reported 2024-03-31.
Showing the 12 most recent filer reports.
8 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Kiniksa Pharmaceuticals International, plc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-28 · Patel Sanj K: Larger than all 50 other insider sales of Class A Ordinary Share on file. SEC filing
- 2026-04-28 · Patel Sanj K: Larger than 49 of the 50 other insider sales of Class A Ordinary Share on file. SEC filing
- 2025-10-31 · Paolini John F.: Larger than 45 of the 50 other insider sales of Class A Ordinary Share on file. SEC filing
- 2025-10-22 · Patel Sanj K: Larger than 47 of the 50 other insider sales of Class A Ordinary Share on file. SEC filing
- 2025-10-20 · Patel Sanj K: Larger than 48 of the 50 other insider sales of Class A Ordinary Share on file. SEC filing
- 2025-09-04 · Tessari Eben: Larger than 46 of the 50 other insider sales of Class A Ordinary Share on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-01 | Paolini John F. · CHIEF MEDICAL OFFICER | Class A Ordinary Share | S — Open market or private sale | −21,097 | 54.04 | SEC filing |
| 2026-05-01 | Paolini John F. · CHIEF MEDICAL OFFICER | Class A Ordinary Share | S — Open market or private sale | −37,327 | 53.52 | SEC filing |
| 2026-05-01 | Patel Sanj K · CHAIRMAN & CEO | Class A Ordinary Share | S — Open market or private sale | −48,565 | 54.02 | SEC filing |
| 2026-04-30 | Patel Sanj K · CHAIRMAN & CEO | Class A Ordinary Share | S — Open market or private sale | −2,141 | 54.01 | SEC filing |
| 2026-04-29 | Patel Sanj K · CHAIRMAN & CEO | Class A Ordinary Share | S — Open market or private sale | −22,544 | 54.01 | SEC filing |
| 2026-04-28 | Patel Sanj K · CHAIRMAN & CEO | Class A Ordinary Share | S — Open market or private sale | −113,673 | 51.47 | SEC filing |
| 2026-04-28 | Quart Barry D · Director | Class A Ordinary Share | S — Open market or private sale | −13,099 | 50.10 | SEC filing |
| 2026-04-28 | Patel Sanj K · CHAIRMAN & CEO | Class A Ordinary Share | S — Open market or private sale | −74,635 | 50.43 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-01 | Patel Sanj K · CHAIRMAN & CEO | Class A Ordinary Share | C — Conversion of derivative security | +900,000 | SEC filing |
| 2026-06-01 | Patel Sanj K · CHAIRMAN & CEO | Class B Ordinary Shares | C — Conversion of derivative security | −900,000 | SEC filing |
| 2026-05-29 | Malley Thomas · Director | Restricted Share Units | M — Exercise or conversion of derivative security | −2,799 | SEC filing |
| 2026-05-29 | McCain Tracey L · Director | Restricted Share Units | M — Exercise or conversion of derivative security | −2,799 | SEC filing |
| 2026-05-29 | Quart Barry D · Director | Class A Ordinary Share | M — Exercise or conversion of derivative security | +2,799 | SEC filing |
| 2026-05-29 | Cole G Bradley · Director | Restricted Share Units | M — Exercise or conversion of derivative security | −2,799 | SEC filing |
| 2026-05-29 | Quart Barry D · Director | Restricted Share Units | M — Exercise or conversion of derivative security | −2,799 | SEC filing |
| 2026-05-29 | Popovits Kimberly J · Director | Restricted Share Units | M — Exercise or conversion of derivative security | −2,799 | SEC filing |
Showing 8 of 34 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.